{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T04:45:50Z","timestamp":1767156350112},"reference-count":32,"publisher":"SLACK, Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Ann"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:p>\n            Intravenous immunoglobulin (IVIG) is given to children with a variety of rheumatologic illnesses. The mechanism of action by which it exerts therapeutic effects is not well understood and likely differs in the medical conditions for which it is given. IVIG is approved by the US Food and Drug Administration and is the standard of care for Kawasaki disease, but most IVIG use in pediatric rheumatology is \u201coff-label. \u201c The literature supports the use of IVIG for juvenile dermatomyositis, although it is unclear whether its use should be limited to those children with more severe or refractory disease. It appears efficacious in the treatment of autoimmune thrombocytopenia secondary to lupus, but its use may be limited by transient responses. Treatment of other categories of pediatric rheumatologic diseases, such as juvenile idiopathic arthritis and non-Kawasaki vasculitides, is not well-established in the literature. This review focuses on current use of IVIG in the treatment of pediatric rheumatologic disorders.\n            <jats:bold>\n              [\n              <jats:italic>Pediatr Ann.<\/jats:italic>\n              2017;46(1):e19\u2013e24.]\n            <\/jats:bold>\n          <\/jats:p>","DOI":"10.3928\/19382359-20161214-01","type":"journal-article","created":{"date-parts":[[2017,1,12]],"date-time":"2017-01-12T14:35:20Z","timestamp":1484231720000},"source":"Crossref","is-referenced-by-count":14,"title":["Intravenous Immunoglobulin in Pediatric Rheumatology: When to Use It and What Is the Evidence"],"prefix":"10.3928","volume":"46","author":[{"given":"Martha M.","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Wagner-Weiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.9.6.722"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1154315"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117520"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12897"},{"issue":"1","key":"e_1_3_1_6_2","first-page":"45","article-title":"Acute renal failure related to intravenous immunoglobulin infusion in an elderly woman","volume":"11","author":"Kwan TH","year":"2005","unstructured":"Kwan TH, Tong MK, Siu YP, et al. Acute renal failure related to intravenous immunoglobulin infusion in an elderly woman. Hong Kong Med J. 2005;11(1):45\u201349.","journal-title":"Hong Kong Med J"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199312303292704"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.72.1.25"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.153718"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20695"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(89)90198-X"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2014.44085"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330825"},{"key":"e_1_3_1_14_2","first-page":"75","article-title":"Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases","volume":"29","author":"Arnal C","year":"2002","unstructured":"Arnal C, Piette JC, L\u00e9one J, et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol. 2002;29:75\u201383.","journal-title":"J Rheumatol"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20120"},{"key":"e_1_3_1_16_2","first-page":"346","article-title":"The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus","volume":"34","author":"Bayraktar UD","year":"2007","unstructured":"Bayraktar UD, Erkan D, Bucciarelli S, Espinosa G, Asherson RCatastrophic Antiphospholipid Syndrome Project Group. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol. 2007;34:346\u2013352.","journal-title":"J Rheumatol"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.03.002"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000185772"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-004-1046-9"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002960000053"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken153"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27308"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.09.044"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330714"},{"issue":"5","key":"e_1_3_1_25_2","first-page":"910","article-title":"Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial","volume":"23","author":"Silverman ED","year":"1996","unstructured":"Silverman ED, Cawkwell GD, Lovell DJ, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. J Rheumatol. 1996;23(5):910\u2013918.","journal-title":"J Rheumatol"},{"issue":"8411","key":"e_1_3_1_26_2","first-page":"1055","article-title":"Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I\/II study","volume":"324","author":"Giannini EH","year":"1984","unstructured":"Giannini EH, Lovell DJ, Silverman ED, et al. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I\/II study. Lancet. 1984;324(8411):1055\u20131058.","journal-title":"Lancet"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198608073150601"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2011-1704"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-200X.1999.t01-1-01014.x"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23147"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2015.1092582"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-010-1518-y"},{"key":"e_1_3_1_33_2","unstructured":"The International Inflammatory Brain Disease Outcome Study 2014 BrainWorks"}],"container-title":["Pediatric Annals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.healio.com\/pediatrics\/journals\/pedann\/2017-1-46-1\/%7B031b6aae-3d9b-405f-80b4-12739717b411%7D\/intravenous-immunoglobulin-in-pediatric-rheumatology-when-to-use-it-and-what-is-the-evidence","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T01:44:13Z","timestamp":1683078253000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/19382359-20161214-01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.3928\/19382359-20161214-01"],"URL":"https:\/\/doi.org\/10.3928\/19382359-20161214-01","relation":{},"ISSN":["0090-4481","1938-2359"],"issn-type":[{"value":"0090-4481","type":"print"},{"value":"1938-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}